ICMR Timeline

डॉ. संतसबुज दास

MBBS, M.D. (General Medicine)
Director & Scientist G, ICMR - NIRBI, Kolkata

लगभग ५४ साल पहले १९६२ में, भारतीय चिकित्सा परिषद (ICMR) द्वारा कॉलरा और अन्य दस्तों के रोगों की रोकथाम और नियंत्रण पर अनुसंधान करने के लिए कॉलरा रिसर्च सेंटर स्थापित किया गया था। १९६८ में इस संस्थान को कोलकाता में कॉलरा चरणों पर उत्कृष्ट अध्ययन के लिए डब्ल्यू.एच.ओ(WHO) द्वारा "विब्रियो फेज टाइपिंग के लिए अंतर्राष्ट्रीय संदर्भ केंद्र" ("International Reference Centre for Vibrio Phage Typing") की दर्जा दिया गया और बाद में, १९७८ में, इसे "विब्रियोस पर संदर्भ और अनुसंधान के लिए डब्ल्यू.एच.ओ का सहयोगात्मक केंद्र" ("WHO Collaborative Centre for Reference and Research on Vibrios") के रूप में नामांकित किया गया था।. View Profile

डॉ. राजीव बहल

भारत सरकार के सचिव, स्वास्थ्य अनुसंधान विभाग और महानिदेशक
भारतीय चिकित्सा अनुसंधान परिषद

डॉ. राजीव बहल एक चिकित्सक-वैज्ञानिक हैं, जो बाल रोग (एम. डी. पीडियाट्रिक्सः दिल्ली विश्वविद्यालय) और सार्वजनिक स्वास्थ्य (पी. एच. डी.: अखिल भारतीय आयुर्विज्ञान संस्थान) में विशेषज्ञता रखते हैं। मातृ और बाल स्वास्थ्य अनुसंधान में उनके योगदान की मान्यता में उन्हें 2022 में नॉर्वे के बर्गन विश्वविद्यालय से मानद डॉक्टरेट की उपाधि प्राप्त हुई।

डॉ. बहल ने पिछले तीन दशकों में स्वास्थ्य अनुसंधान में नेतृत्व का प्रदर्शन किया है और भारत और वैश्विक स्तर पर सार्वजनिक स्वास्थ्य नीति में अनुसंधान का अनुवाद किया है। उनके विपुल विद्वतापूर्ण उत्पादन में सहकर्मी समीक्षा पत्रिकाओं में 250 से अधिक शोध पत्र और 78 का एच-इंडेक्स शामिल है जो उन्हें सभी विषयों में दुनिया के शीर्ष वैज्ञानिकों में स्थान देता है। View Profile

संवाद एवं कार्यक्रम

• Webinar to assist candidates in understanding the Revised Centralised Interview Process

  AcSIR-Announcement for a webinar in order to assist candidates in understanding the Revised Centralised Interview Process, conducted by the Dean's Office with important instructions and Q&A session.
  Date: Friday, 13th June 2025
  Time: 3:00 PM IST
  Webex Link: https://nimr.webex.com/nimr/j.php?MTID=m9787627d84d1505a1a4ff5825507569f
  
  Participation in the webinar is highly recommended to clarify any queries related to the interview process.

Impact assessment of administering Oral Cholera Vaccine in selected cholera vulnerable districts of West Bengal.

- An Vaccine implementation Research by ICMR- NICED in collaboration with State Public Health System, Govt of West Bengal.

Cholera remains a global public health problem with developing countries bearing the burnt many folds. WHO - Global Task Force on Cholera Control (GTFCC) has declared to End Cholera by 2030 to which India is also committed as a Nation.

Prevention of Cholera outbreak always remained a challenge in countries like India where there are lots of slum populations with high population density. Achieving cholera control through improving water, hygiene, and sanitation may not be feasible at times and require sustained effort and commitment. In such a situation, the Oral Cholera Vaccine (OCV) is an important intervention to address immediately the cholera outbreak menace.

In this regard, ICMR-NICED Kolkata is taking the initiative through an ICMR-funded project for health system implementation of OCV in selected cholera-vulnerable districts of West Bengal utilizing the state health machinery so that effectiveness, challenges, and future policy decisions on requirements of programmatic introduction of OCV may be monitored from real health system perspective.

Euvichol-Plus is an OCV containing inactivated whole cell (WC) of Vibrio cholerae O1 and O139 as active ingredients. It is very safe and around 65% efficacious as evidenced from earlier Randomized Control Trials. The study vaccine (Euvichol-Plus) has been registered in multiple countries, with WHO prequalification for use in subjects 1 year and above. Euvichol-Plus has been procured from UN agencies at subsidized rate, comprising more than 90% of OCV supply to cholera-endemic countries worldwide.

The primary objective is to evaluate the impact of OCV implementation in cholera-endemic zones of West Bengal in a real time situation through a mass vaccination campaign using the public healthcare delivery system. Other specific research components will also be included, like :

• Age group of target population: children of 1 year and above from cholera-endemic areas, excluding pregnant/lactating women and seriously ill individuals.
• Oral cholera vaccine (OCV), Euvichol-Plus, will be administered through urban municipality primary health centres or other booths at selected Urban wards (areas with dense clusters in city study map above) with a dosing schedule of Day 0 and Day 14, targeting a total population of around 50,000.
• The vaccine, WHO-prequalified in 2017, has demonstrated sufficient safety and immunogenicity.
• Post-vaccination, diarrhoeal disease surveillance network will be in place to monitor and document diarrheal episodes through.

COVID-19 Status Update ICMR-NICED

View all updates

Information Regarding Testing of Samples for SARS-CoV-2 in the Emergency Situation
View COVID-19 Guidelines: Information Regarding Testing of Samples for SARS-CoV-2 in the Emergency Situation

Guideline for sending suspected monkey pox samples

View Guideline for sending Monkeypox suspected samples to NICED

ANNEXURE I | ANNEXURE II | ANNEXURE III

About NICED

NICED moved from the rented premises at No. 3 Kyd Street to its own establishment at P-33, C.I.T. Road, Scheme XM, Beliaghata, Kolkata 700010, adjacent to the Infectious Diseases Hospital. The unique feature of this Institute is that it conducts basic research and applied clinical and epidemiological research on diarrhoeal diseases under the same roof. This Institute has its basic science set up with well equipped, modern technological facilities in different disciplines such as bacteriology, virology, parasitology, biochemistry, pathophysiology, molecular biology, electron microscopy, immunology and biochemistry.  Read more...

Notifications